OHSU

IRB #

IRB00009414

Title

A Phase III Study of FOLFIRINOX with or without Hyperacute-Pancreas (Algenpantucel-L) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

Principal Investigator

Gina Vaccaro

Study Purpose

To compare the effects of standard-of-care therapy (FOLFIRINOX) with or without the addition of HyperAcute-Pancreas (experimental) immunotherapy to find out which is better.

Medical Condition(s)

Pancreatic cancer

Eligibility Criteria

1. Male or female age 18 years or older
2. Confirmed diagnosis of pancreatic cancer
3. Cancer must be borderline surgically removable (may or may not be completely successful) or cannot be surgically removed
4. Other criteria apply

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

2 - 12 months (treatment period)
Up to 10 years (follow-up)

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

NewLink Genetics Corporation

Recruitment End

12/31/2015

Compensation Provided

No


Go Back